期刊文献+

抗肿瘤药与消化道肿瘤化疗患者感染风险的Logistic回归分析 被引量:1

Logistic Analysis of the Infectious ODDS Risks of Anticancer Drugs in GI Cancer Patients with Chemotherapy Regiments
下载PDF
导出
摘要 目的:研究抗肿瘤药与消化道恶性肿瘤化疗患者感染发生风险的关系。方法:收集符合条件的消化道肿瘤化疗患者2384例,用Logistic回归分析不同种类化疗药物等因素对患者发生感染的风险性的相关性。结果:年龄、住院天数、费别、烷化剂、金属络合物、其他抗肿瘤药的回归系数分别为0.010,0.147,-0.361,-.930,- 0.390,-1.306。结论:年龄和住院天数都对感染发生产生正相关作用,参加医保可以降低感染的发生风险,抗肿瘤抗生素、植物来源抗肿瘤药物、抗代谢抗肿瘤药物比金属络合物抗肿瘤药物、烷化剂和其他类抗肿瘤药物在化疗期间具有较高的感染发生风险比。 Objective: To analyze the infectious ODDS risks of anticancer plant alkaloids and other anticancer drugs in GI cancer patients with chemotherapy regiments. Method: 2384 profiles of cancer patients agreeable with studying condition were collected. All the profiles were evaluated with different variants, and then these variants were analyzed with the logistic liner. Result: The line values of ages, days in hospital, insurances, alkylating agents, platinum antitumor compounds and other antitumor drugs were 0.010,0. 147,43.361,43. 930, 43.390, and -1. 306. Conclusion: The infection OR of the ages and days in hospital increased OR factors and the medical insurances decreased OR factors. Antitumor antibiotics, antimetabolites, plant alkaloids had their higher infectious risks than platinum antitumor compounds, alkylating agents and other antitumor drugs did in GI cancer patients with chemotherapy regiments.
出处 《药物流行病学杂志》 CAS 2008年第1期20-23,共4页 Chinese Journal of Pharmacoepidemiology
基金 青岛市卫生局立项课题(2004-WSJH001)
关键词 抗肿瘤药 消化道肿瘤 感染 LOGISTIC回归 Antitumor drugs GI cancer Infection Logistic analysis
  • 相关文献

参考文献10

  • 1孙燕,周际昌.临床肿瘤内科手册[M].第4版.北京:人民卫生出版社,2006.264-288.
  • 2Sorensen JB, Clerici M, Hansen HH. Single-agent chemotherapy for advanced adenocarcinoma of the lung[ J]. Cancer Chemother Pharmacol, 1988,21 ( 2 ) :89-102.
  • 3刘新春,程玉峰,李德爱.实用抗肿瘤药物治疗学[M].北京:人民卫生出版社,2004.113-402.
  • 4金丕焕.医用统计方法[M].第2版.上海:复旦大学出版社,2004.337-450.
  • 5Dancey J, Eisenhauer EA. Current perspectives on camptothecins in cancer treatment[ J]. Br J Cancer, 1996,74 ( 3 ) : 327-338.
  • 6杨莉,汪少娟,杨业金,陈忠,吴燕丽.抗肿瘤药对膀胱癌细胞产生的免疫抑制因子作用的影响[J].药物流行病学杂志,2000,9(3):124-125. 被引量:4
  • 7Jones JA, Avritseher EB, Cooksley CD. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer[ J ]. Support Care Cancer,2006,14 (6) :505-515
  • 8Ludbrook JJ, Truong PT, MacNeil MV, et al. Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer, a community-based population analysis [ J ]. Int J Radiat Oneol Biol Phys, 2003,55 (5) : 1321-1330.
  • 9杨松,张万年.高喜树碱——极具开发价值的拓扑异构酶Ⅰ抑制剂[J].药学学报,2004,39(5):396-400. 被引量:8
  • 10郑应馨,徐恒卫,项宇峰,舒心.抗肿瘤药物与相关代谢酶[J].中国药师,2006,9(5):466-468. 被引量:8

二级参考文献47

  • 1张月桂,刘军,唐亚莉,李殿俊,龙庆山,薛英威,王贵奇,赵家宏.rIL-2/LAK细胞治疗晚期恶性肿瘤[J].肿瘤防治研究,1995,22(1):12-13. 被引量:3
  • 2徐红霞,陈兆聪,王茹端,韩玲,周荣章.癌症患者血清免疫抑制活性及其动态观察[J].癌症,1989,8(5):342-345. 被引量:8
  • 3Raymond E, Campone M, Stupp R, et al. Multicentre phase Ⅱ and pharmacokinetic study of RFS2000 (9-nitrocamptothecin) administered orally 5 days a week in patients with glioblastoma nultiforme [J] . Eur J Cancer, 2002,38(10) :1348- 1350.
  • 4Giles FJ, Cortes JE, Thomas DA, et al. Phase I and pharmacokinetic study of DX-8951 f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia [J]. Clin Cancer Res,2002,8(7) :2134 - 2141.
  • 5Kehrer DF, Bos AM, Verweij J, et al. Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity [J]. J Clin Oncol,2002,20(5): 1222 - 1231.
  • 6Laregne O, Lesueur-Ginot L, Rodas FP, et al Homocamptothecin: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues [J]. J Med Chem,1998,41(27) :5410 - 5419.
  • 7Cao Z, Harriss N, Kozielski A, et al. Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity [J]. J Med Chem, 1998,41(1) :31-37.
  • 8Bom D, Curran DP, Chavan AJ, et al. Novel A, B, Ering-modified camptothecins displaying high lipophilicity and markedly improved human blood stabilities [J]. J Med Chem, 1999,42(16) :3018-3022.
  • 9Lavergne O, Lesueur-Ginot L, lRodas FP, et al. BN80245:an E-ring midified camptotehein with potent antiproliferative and topoisomerase I inhibitory activities [J]. Bioorg Med Chem lett, 1997,7(17) :2235 - 2238.
  • 10Lesueur-Ginot L, Demarquay DD, Kiss R, et al.Homocamptotheein, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase l-targeted activity aud antitumor properties [J]. Cancer Res, 1999,59(12) :2939 - 2943.

共引文献19

同被引文献16

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部